Slides
Page 1
AnteoBind market opportunities & partnership landscape Life Sciences Business | Investor Presentation 22 October 2026 AnteoBind
Page 2
LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 2 Disclaimer IMPORTANT INFORMATION The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX: ADO) (AnteoTech). These slideshave been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly availablesources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Past performance is not indicative of future performance. FORWARD-LOOKING STATEMENTS The presentation may contain certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech’s business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group. NOT AN OFFER OF SECURITIES This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied uponas advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision. This presentation has been approved for release to the ASX by the Board of AnteoTech. AnteoBind NXT, Anteo X®, Anteo S and Ultranode® are trademarks of AnteoTech. The use of registered and pending trademark symbols throughout the presentation is implied. All $ quoted are AUD unless otherwise stated.
Page 3
LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 3 Who We Are Chemical and Advanced Material solutions For life sciences and next-generation batteries One proprietary chemical platform Two global markets Multiple opportunities Life Sciences Battery Technologies Established in 2000 Publicly listed company ASX: ADO (in 2006) Established commercial supply relationships to global diagnostic customers Laboratories, testing facilities & Pilot Plant COMPANY INTRODUCTION
Page 4
LS INVESTOR PRESENTATION| 22 OCTOBER 2026 | ©AnteoTech Limited 4 Capital Structure and Corporate Overview Share Price – 6 months to 19 October 2026 Directors Glenda McLoughlin Non-Executive Chair Investment Banker with Morgan Stanley, Credit Suisse and Barclays. Commercial Advisor and ASX Founder. Energy and Infrastructure sector expertise. Dr. Geoff Cumming Non-Executive Director Career spanning research to sales and marketing and Executive roles with Roche Also on INOVIQ Ltd (IIQ) Board. Biotechnology and Healthcare sector expertise. Merrill Gray Managing Director/CEO ASX Founder and MD/CEO. Energy incl. Battery (CAM (LFP/LMFP), Graphite and Recycling) plus Hydrogen and Renewables experience. Capital Structure (as at 19 October 2026) Shares Unlisted Options 3,265.1 million 233.5 million (7% expire in 2026, 65% in 2028). Employee/Director options 39% Market Capitalisation $49 m as at 19 October 2026 Top 20 Holders Hold 20% of shares Cash in Bank $11.2 million total as at 30 June 2026 (including Term Deposits) COMPANY OVERVIEW Source: https://www.asx.com.au/markets/company/ADO
Page 5
LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 5 AnteoTech’s Life Sciences Products Early revenue business, operating in target markets which have~US$90 billion in sales annually1 Established and growing business Proprietary technology Innovating for the next generation of diagnostics Advanced chemical and materials solutions business Headquartered in Brisbane, Australia AnteoBindTM Product Portfolio AnteoBindTM NXT– Next-generation technology that improves assay performance and manufacturing efficiency. AnteoBind ELISA Reagents and Plates - Reagents and activated microplates for ELISA applications. Biosensor – Surface chemistry technology for electrodes and other specialised diagnostic surfaces. AnteoBind delivers substantial improvements to In Vitro Diagnostics (IVD) developers Up to 90% reduction in antibody requirements for assays Up to 45 times higher signal compared to traditional chemistries Stable coating for >12 months Enhanced compatibility and specificity Reduced wastage and shortened development timelines Two businesses: Life Sciences and Advanced Battery Technologies COMPANY INTRODUCTION AnteoBindTM – Proprietary surface chemistry technology that binds antibodies and other biomolecules to diagnostic surfaces. Multiplex Activation Kit - Optimised particle activation in multiplex diagnostic applications. 1= Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company
Page 6
LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 6 Global Commercialisation Strategy Regional commercial strategy and market priorities. Existing markets New opportunities USA Europe India South Korea & Japan USA Europe India South Korea & Japan Strategy ● Grow our customer base ● Attract strategic partners Batteries ● Ultranode 95: defence and security drones ● Manned & unmanned aerial systems (UAS) ● Carbon nanotube JDA (SiMRAX) Life Sciences ● Point-of-care diagnostics, CLIA and ELISA markets Strategy ● Grow customer base ● Attract strategic partners Batteries ● WYON Ultranode 70 evaluation and validation ● New customers Life Sciences ● Global life sciences company engagement: lateral flow, CLIA and ELISA Strategy ● Sales growth ● Secure strategic partnerships using a profit repatriation model Batteries ● Ultranode and performance additives: e-mobility and wearables ● Large-scale battery material manufacturer supply ● Joint product development (JDA) Life Sciences ● Expand Serum Institute of India relationship and secure similar customers ● Work with Austrade and Trade and Investment Queensland (TIQ) Strategy ● Expand our customer base and sales ● Attract strategic partners Batteries ● Market entry ● Distributors supporting growth ● Austrade and TIQ support Life Sciences ● Distributors supporting growth ● Austrade and TIQ support Source: ASX release, 10 June 2025, Strategic Review Outcomes TIQ: Trade and Investment Queensland. JDA: Joint development agreement. COMPANY INTRODUCTION
Page 7
LS INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 7
Page 8
LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 8 AnteoTech’s commercial position today in the Life Sciences market TODAY Established Commercial Supply/Revenues Five -year take -or-pay US$ 1.8 million supply agreement with the Serum Institute of India signed in mid 2024. Growing International Distribution Network Established distributor arrangement, including Cosmo Bio in Japan and KOMA in South Korea Paid Development Collaboration CLIA development program with a major global Life Sciences company in progress Expanding Customer Pipeline Customer engagement and sample evaluations underway with Sales Qualified Leads (SQL) across four diagnostic platforms. Where we are heading …
Page 9
© AnteoTech Limited Lateral Flow: Broad Customer Base Across Global Diagnostics Markets AnteoBind supports antibody conjugation to particles used in rapid diagnostic tests. GLOBAL MARKET SIZE (2024) US$15.5B DISCUSSIONS UNDERWAY (SQL) 17 Across manufacturers, developers and research organisations ANTEOBIND TM APPLICATION Latex & Gold Antibody conjugation for multiple particle types for conjugation in rapid diagnostic tests IMMUNOASSAY MARKET BY PLATFORM (US$B: 2024) US$15.5B US$13B US$21B US$6.5B LF & other* CLIA ELISA FIA 2 Large-Scale Manufacturers Indian operations of a global IVD group and contract development/manufacturing company’s in Spain and the UK 5 Established Diagnostics Companies Diagnostic test manufacturers across Canada, France, Spain, the United States and India 8 Emerging and Specialist Developers Developers of rapid diagnostic technologies, including companies in Finland and India 2 Academic and Research Partners Australian university collaboration and Indian national research institute Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates shown in US dollars for 2024. Market figures represent broader diagnostic segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may be represented across multiple application categories. Names withheld. 9 LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER
Page 10
© AnteoTech Limited CLIA: Engaging with Global Diagnostic Manufacturers AnteoBind supports antibody conjugation to magnetic beads used in automated chemiluminescence immunoassays (CLIA). GLOBAL MARKET SIZE (2024) US$13B Estimated 6% CAGR to 2029* 9 Including four major global IVD manufacturers ANTEOBIND TM APPLICATION Magnetic Beads Antibody conjugation for automated CLIA assays GLOBAL DIAGNOSTIC MARKET SEGMENTS: (US$B, 2024) US$15.5B US$13B US$21B US$6.5B LF & other* CLIA ELISA FIA GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER 4 Major Global IVD Manufacturers Diagnostic analyser manufacturers headquartered in Japan, the United States, Spain and Italy 1 Multinational Diagnostics Group Indian operations of a global diagnostics manufacturer 2 Established IVD Manufacturers Canadian multi-platform diagnostic test manufacturer and established Indian IVD company 2 Specialist and Emerging Developers Haemostasis diagnostics specialist and Indian multi-platform assay developer Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates in US dollars for 2024. Market figures represent broader diagnostic segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld. 10LS INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited DISCUSSIONS UNDERWAY (SQL) LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026
Page 11
© AnteoTech Limited ELISA: Expanding Opportunities in Diagnostic Microplates AnteoBind surface chemistry supports antibody and antigen immobilisation on microplates used in ELISA diagnostic assays. GLOBAL MARKET SIZE (2024) US$21B Estimated 5% CAGR to 2029* 2 Both organisations active across multiple diagnostic platforms ANTEOBIND TM APPLICATIONS Microplates Surface activation for antibody and antigen immobilisation GLOBAL DIAGNOSTIC MARKET SEGMENTS: (US$B, 2024) US$15.5B US$13B US$21B US$6.5B LF & other* CLIA ELISA FIA 1 Established IVD manufacturer Diagnostic manufacturer supplying rapid tests, ELISA and CLIA kits 1 Emerging Diagnostic Developer Developer of diagnostic assays across ELISA, lateral flow and other platforms Commercialisation: This is a recent offering, still at prototyping/early market entry stage, that would expand AnteoBind applications into ELISA microplates. Source: Markets and Markets, In Vitro Diagnostics Market (May 2025); market estimates in US dollars for 2024. Figures represent broader diagnostic market segments and are not AnteoTech-specific addressable markets. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld. 11 DISCUSSIONS UNDERWAY (SQL) LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 GLOBAL CUSTOMER ENGAGEMENT BY ORGANISATION TYPE AND NUMBER
Page 12
© AnteoTech Limited Biosensors: Expanding AnteoBind into Emerging Diagnostic Applications AnteoBind supports the immobilisation of biomolecules on sensor surfaces for potential biosensor applications. GLOBAL MARKET SIZE (2025) US$34.5B Estimated 9.5% CAGR to 2030 across all biosensor applications* 3 Research and technology organisations identified ANTEOBIND TM APPLICATION Sensor Surfaces Biomolecule immobilisation for biosensor development GLOBAL BIOSENSORS MARKET: 2025 TO 2030 (US$B) US$34.5B US$54.4B 2025 2030 (forecast) POTENTIAL COLLABORATION PARTNERS 1 Australian Biosensor Research Network Participating in a national research hub connecting six universities and more than 20 industry partners (MOBIUS) 1 Government Research Institute Indian pharmaceutical research institute with activities spanning biosensors and lateral flow diagnostics (NIPER) 1 Life Sciences Technology Provider Indian company specialising in genomics and cell biology technologies Source: MarketsandMarkets, Biosensors Market (July 2025). Market estimates cover all biosensor applications, including wearables and glucose monitoring, and do not represent AnteoTech's directly addressable market. Organisation counts are based on AnteoTech's internal analysis; organisations may appear across multiple application categories. Names withheld. 12 DISCUSSIONS UNDERWAY (SQL) LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026
Page 13
© AnteoTech Limited Multiple Applications, Expanding Commercial Opportunities One proprietary surface chemistry platform and customer engagement globally across established and emerging diagnostic markets and applications. LIFE SCIENCES INVESTOR PRESENTATION | 22 OCTOBER 2026 LATERAL FLOW 17 CLIA 9 ELISA 2 BIOSENSORS 3 Latex and gold particle conjugation for rapid diagnostic tests Magnetic bead activation for automated immunoassays Activated microplates for antibody and antigen immobilisation Biomolecule immobilisation on sensor surfaces COMMERCIALISATION PRIORITIES Expansion in established Diagnostic Markets Progress customer sample evaluations and pursue commercial supply agreements across Lateral flow, CLIA and ELISA. Emerging Applications Explore opportunities to integrate AnteoBind into biosensors and next-generation diagnostic platforms. 13
Page 14
© AnteoTech Limited 14 LS INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited Supply partnerships can bring AnteoBind to large and established IVD customer bases PARTICLE MANUFACTURERS 3 potential partners are being engaged with Global OEM reagent manufacturer Europe Supplies gold colloid, conjugates and IVD reagents to lateral flow and immunoassay developers Fit Lateral flow · CLIA · ELISA Life sciences multinational Europe Supplies microspheres and magnetic beads to IVD manufacturers Fit CLIA · Lateral flow · Multiplex Microsphere specialist China Potential supplier of magnetic and fluorescent microspheres for CLIA and biopharma at production scale Fit CLIA · Multiplex · Bioseparation FURTHER PARTNERSHIP CHANNELS 4 Multiplex bead assays / LUMINEX Diagnostics, pharmaceutical and vaccine companies across India, Europe 3 Bioseparation European manufacturers of microspheres, agarose-bead and separation technologies 2 Fluorescence immunoassay IVD assay developer and vaccine manufacturer in India 1 Indian developer of Point- of-care microfluidic diagnostic devices Note: Organisation counts: AnteoTech analysis of 35 organisations. Organisations may appear in multiple categories. Names withhe ld. Imagery illustrative. Expanding Market Reach Through Potential Life Sciences Partnerships Microfluidics
Page 15
© AnteoTech Limited 15 LS INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited Moving beyond reagent supply to integrate and embed AnteoBind into assays and new platforms Surface chemistry Particles & plates New diagnostic platforms TODAY Reagent sold to diagnostic manufacturers MOVE 1 Co-developed products MOVE 2 Designed in from day one RESULT AnteoBind in more products 1 Partner with particle & plate makers Co-develop AnteoBind -activated particles and plates ● Supply pre-activated particles and plates to IVD manufacturers ● Access established customer bases through partners ● Secure co-branded, white-label or recurring supply agreements 3 particle manufacturers already identified 2 Embed AnteoBind during new diagnostic platform development ● Incorporate AnteoBind early in assay & platform development ● Support long term adoption through customer validation Early-stage developers identified across platforms Value chain stages and imagery are illustrative. Organisation counts: AnteoTech analysis. Names withheld. Expanding AnteoBind across the Diagnostics Value Chain Collaborate with diagnostic developers
Page 16
Contact: Merrill Gray investors@anteotech.com +61 (07) 3219 0085 www.anteotech.com THANK YOU